Organ-on-chip Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Organ-on-chip Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The global organ-on-chip market is expected to witness a CAGR of 30% over the forecast period (2022-2027).

The research community and the biopharmaceutical industry have mobilized with unprecedented speed against the COVID-19 pandemic. Hence, organ-on-chip is founded to be one of the most promising and go-to technology during the development of vaccines and drugs that have been currently under clinical studies for the treatment of infection. For instance, in March 2020, as a part of the World Health Organization’s (WHO) Research and Development Blueprint response to the COVID-19 outbreak, the emulate lung chip was used to provide preclinical insights into the efficacy of hydroxychloroquine for COVID-19.

An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional 2D and 3D culture systems. It offers a wide range of applications, such as disease modeling, patient stratification, and phenotypic screening.

The organ-on-chip market is driven by factors such as a requirement for alternatives for animal testing, the need for early detection of drug toxicity, and new product launches and advancements in technology that are also responsible for driving the market. For instance, in December 2020, CN Bio and the University of Melbourne collaborated to advance therapies through lung-on-a-chip technology for respiratory complications among patients who have recovered from COVID-19.

In addition, in October 2020, BioVox raised awareness through an initiative to promote organ-on-chip technology for the improvisation of in vitro research models and for reducing animal testing. Moreover, in November 2021, AIM Biotech launched the idenTx 40 Plate, a high-throughput organ-on-a-chip system that lets researchers at biotechnology and pharmaceutical companies faithfully recreate the function of human organs and tissues without using animals for research.

The demand for personalized medication and the vast applications of organ-on-chip beyond the pharmaceutical industry are the major factors creating growth opportunities for market players. However, the complexity of organ-on-chip models may hinder market growth over the forecast period.

Key Market TrendsLung-related Application is Expected to Exhibit a Good Growth Rate Over the Forecast Period

The recent global COVID-19 pandemic caused by the novel coronavirus, SARS-CoV-2, necessitates rapid advances in research and development activities for different approaches to treating the infection. For instance, in April 2020, researchers at the Wyss Institute demonstrated that human airway organ chips could be used to model COVID-19 and the immune response toward the same to test the effectiveness of drugs to curb the infection.

The development of new solutions to treat pulmonary diseases is currently of primary importance, as pulmonary diseases are found to be among the most dreadful conditions globally. According to the World Health Organization’s Global Tuberculosis Report updated in October 2021, in 2020, an estimated 10 million people fell ill with tuberculosis (TB) worldwide. 5.6 million men, 3.3 million women, and 1.1 million children. TB is present in all countries and age groups. Moreover, as per the same source, In 2020, the 30 high TB burden countries accounted for 86% of new TB cases. Eight countries account for two-thirds of the total, with India leading the count, followed by China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa.

The lung-on-chip technology is a complex, three-dimensional model of a living, breathing human lung on a microchip. This device, made up of human lung and blood vessel cells, can predict the absorption of airborne nanoparticles and mimic the inflammatory response triggered by microbial pathogens.

The device can also be used to test the effects of environmental toxins, absorption of aerosolized therapeutics, and the safety and efficacy of new drugs. It is expected to become an alternative to animal testing.

With the combination of microfabrication techniques with modern tissue engineering, lung-on-chip also offers a new in vitro approach to drug screening by mimicking the complicated mechanical and biochemical behaviors of a human lung.

Hence, despite having already proven its worth, the lung-on-chip technology may also need to be engineered further, perhaps with muscle cells, to help test the effects of any treatment on the lungs, which may result in further growth of the market.

North America Captured the Largest Market Share and is Expected to Retain its Dominance Over the Forecast Period

The COVID-19 pandemic accelerated the use of organ-on-chip usage for the development and testing of drugs. The market has witnessed various collaborations between research institutes and market players. For instance, in October 2020, the United States Food and Drug Administration entered a collaborative agreement to use lung chips from Emulate Inc. to evaluate the safety of COVID-19 vaccines and protective immunity against SARS-CoV-2.

Similarly, in October 2020, researchers at the United States Army Combat Capabilities Development Command (CCDC) and Chemical Biological Center (CBC) used Emulat’s lung-on-chip technology for research on COVID-19.

Currently, North America dominates the organ-on-chip market, owing to factors such as the availability of a wide range of services offered by major players (which includes customized designing of new chips with specific organ arrangements) and an increase in toxicological testing of chemicals on the different types of organ cells. Huge investments are being made by public and private institutes for their research.

For instance, several research institutions are actively involved in research and further advancing the technologies for organ-on-chip in North America. For instance, in March 2020, researchers at the Massachusetts Institute of Technology (MIT) created a new model for organs-on-a-chip that could be a crucial step in developing treatments for inflammatory diseases and afflictions.

In March 2021, AIM Biotech launched a contract research service, which uses its organ-on-a-chip technology to accelerate and improve drug discovery and development. This further increased the growth in the market studied.

Thus, all aforementioned factors are expected to boost the market in the region over the forecast period.

Competitive Landscape

The organ-on-chip market is highly competitive and consists of several major players. In terms of market share, a few of the major players currently dominate the market. The presence of major market players, such as AxoSim Inc., BiomimX SRL, Elveflow, Emulate Inc., Hurel Corporation, InSphero AG, MIMETAS BV, Nortis Inc., Tara Biosystems Inc., and TissUse GmbH, is, in turn, increasing the overall competitive rivalry in the market. Product advancements and improvements in the organ-on-chip platforms by the major players are increasing the competitive rivalry.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.